Individuals (RE1) Class of Business: Long Term Insurance & Investment (Advantage) Updated CPD points Experience 2 Years...’ Experience in the Insurance Industry Experience in Category A, B1, B2, C and Retail Benefits Fit and Proper Rep for all Tier 1...
the pet insurance products to interested clients giving them the best options for their “fur babies” Claims... Ability to acquire new skills No insurance experience? No problem, we will provide successful applicants with all the necessary tools...
Conduct Outbound/Inbound/Funeral policy sales. Initiate the customer relationship and meet various KPIs. Connect with the customer, conduct needs analysis and propose customer solutions. Consultant requires a solid knowledge of products...
in the Banking, Insurance, Asset Management and Funds industries. As a BDO Financial Services professional, you’ll work..., funds and insurance companies; Hands on experience with clients and management; Open door policy with managers...
Chile, home to the world’s biggest lithium reserves, is confident that investors will compete for licenses to drill new deposits even amid a worsening global glut that’s squeezing the battery-metal industry. Continue Reading »
Gold Prices Today: Gold of 99.9 and 99.5 per cent purity grew ₹2,320 each in the last seven trading sessions. However, silver prices declined ₹500 to ₹93,500 per kg from the previous close Continue Reading »
At 11:57 a.m. ET, the Dow Jones Industrial Average rose 0.58 per cent, the S&P 500 gained 0.14 per cent, the Nasdaq Composite lost 0.19 per cent Continue Reading »
Expert view: Mohit Khanna anticipates the Union Budget 2025 will prioritize youth, women, the poor, and farmers, with increased spending on rural housing, irrigation, and employment-linked incentives. Continue Reading »
HPCL Q3 Results: The state-owned OMC's revenue from operations in the third quarter of current fiscal rose to ₹1.10 lakh crore led by better marketing margins. Continue Reading »
Dr Reddy's Laboratories reported a 2% YoY increase in PAT to ₹1,413.3 crore for Q3 2024, driven by a 16% rise in revenue to ₹8,358.6 crore. The company invested ₹6.7 billion in R&D, focusing on complex generics and biosimilars. Continue Reading »